Drugs / QL2108
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06614907 | Aug → Nov 2024 | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06884891 | Apr 2025 → May 2027 expected | atopic eczema | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL2108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06614907 ↗ |
| Route | Subcutaneous | “QL2108 injection; 300mg/2.0mL; subcutaneous injection” NCT06614907 ↗ |